Intraindividual response to treatment with pirfenidone in idiopathic pulmonary fibrosis

American Journal of Respiratory and Critical Care Medicine

Volumn 191, Issue 1, 2015, Pages 110-113

  Loeh, Benjamin ^a   Drakopanagiotakis, Fotios ^b   Bandelli, Gian Piero ^c   Von Der Beck, Daniel ^b   Tello, Silke ^b   Cordani, Elisa ^c   Rizza, Elvira ^c   Barrocu, Laura ^c   Markart, Philipp ^b   Seeger, Werner ^b   Guenther, Andreas ^a,b   Albera, Carlo ^c  

^a Agaplesion Pneumologische Klinik Waldhof Elgershausen   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PIRFENIDONE; ANTIFIBRINOLYTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE;

AGED; ARTICLE; FEMALE; FIBROSING ALVEOLITIS; HUMAN; LUNG FUNCTION; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; TREATMENT RESPONSE; DRUG EFFECTS; GERMANY; IDIOPATHIC PULMONARY FIBROSIS; ITALY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RETROSPECTIVE STUDY; TOTAL LUNG CAPACITY; TREATMENT OUTCOME; VITAL CAPACITY;

ADMINISTRATION, ORAL; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIFIBRINOLYTIC AGENTS; FEMALE; GERMANY; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; ITALY; MALE; MIDDLE AGED; PYRIDONES; RETROSPECTIVE STUDIES; TOTAL LUNG CAPACITY; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84920409063     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201406-1106LE     Document Type: Article

References (14)

1. Meltzer EB, Noble PW. Idiopathic pulmonary fibrosis. Orphanet J Rare Dis 2008;3:8.
2. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, et al.; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/ JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
3. Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003;168:538-542.
4. Kim DS, Collard HR, King TE Jr. Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc 2006;3:285-292.
5. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, et al.; CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011;377:1760-1769.
6. Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, Taguchi Y, Takahashi H, Nakata K, Sato A, et al.; Pirfenidone Clinical Study Group in Japan. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010;35:821-829.
7. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, et al.; ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2083-2092.
8. Loeh B, Drakopanagiotakis F, Bandelli GP, Cordani E, Tello S, von der Beck D, Seeger W, Markart P, Guenther A, Albera C. Intraindividual response to treatment with pirfenidone in two independent European IPF cohorts. Presented at the ERS International Congress Munich 2014. September 6-10, 2014, Munich, Germany. Poster 762.
9. du Bois RM, Nathan SD, Richeldi L, Schwarz MI, Noble PW. Idiopathic pulmonary fibrosis: lung function is a clinically meaningful endpoint for phase III trials. Am J Respir Crit Care Med 2012;186:712-715.
10. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, King TE Jr, Lancaster L, Noble PW, Sahn SA, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med 2011;184:1382-1389.
11. Chapman HA. Disorders of lung matrix remodeling. J Clin Invest 2004;113:148-157.
12. Fernandez IE, Eickelberg O. New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis. Lancet 2012;380:680-688.
13. Ghofrani HA, Morrell NW, Hoeper MM, Olschewski H, Peacock AJ, Barst RJ, Shapiro S, Golpon H, Toshner M, Grimminger F, et al.; Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 2010;182:1171-1177.
14. Nkyimbeng T, Ruppert C, Shiomi T, Dahal B, Lang G, Seeger W, Okada Y, D'Armiento J, Günther A. Pivotal role of matrix metalloproteinase 13 in extracellular matrix turnover in idiopathic pulmonary fibrosis. PLoS ONE 2013;8:e73279.